GlassScriptPhysician profile
Melessa Mattis
NPI 1467908947
$1,740.01
in general payments reported to CMS, 2019-2025
21 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $557 · 2024: $422 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $317.72 | 2023-2024 | Epclusa, Descovy, Biktarvy |
| Lilly USA, LLC | $250.97 | 2022-2025 | Mounjaro, Zepbound |
| Viiv Healthcare Company | $225.75 | 2023-2025 | Dovato, Apretude |
| Astrazeneca Pharmaceuticals LP | $157.35 | 2022-2023 | Farxiga |
| Amgen INC. | $153.96 | 2023-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $113.79 | 2023 | |
| Fresenius USA Marketing, INC. | $109.29 | 2022 | |
| Silk Road Medical, INC. | $79.70 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Shield Therapeutics INC | $46.42 | 2025 | |
| Dynavax Technologies Corporation | $45.79 | 2024-2025 | Heplisav-B |
| Pfizer INC. | $36.01 | 2025 | |
| Dexcom, INC. | $28.05 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $23.87 | 2025 | Capvaxive, Gardasil 9 |
| Janssen Biotech, INC. | $23.80 | 2023 | Symtuza |
| Hologic Sales and Service, LLC | $23.14 | 2025 | Aptima |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.73 | 2025 | Caplyta |
| Exact Sciences Corporation | $21.15 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $16.87 | 2024 | |
| Novo Nordisk INC | $15.65 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $15.41 | 2023 | |
| Glaxosmithkline, LLC. | $13.59 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melessa Mattis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.